Navigation Links
Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
Date:9/3/2013

SUNNYVALE, Calif., Sept. 3, 2013 /PRNewswire/ -- Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) held a successful meeting with DHK Medical Products CEO in California. DHK Medical Products offers technologically advanced products and services for the healthcare sector in India.

Following the meeting, Arrayit is confident of doing significant business with DHK Medical. The company believes that there is potential to generate $3 million from selling its tests to DHK Medical in the first year. Sales could increase to $5 and $8 million in the second and third year respectively, and go up to $10 million annually thereafter.

In June 2013, ARYC and DHK Medical signed an exclusive three-year distributorship agreement, under which DHK Medical will sell ARYC's genomic tests in India, one of the fastest growing healthcare markets in the world. 

DHK plans to offer Arrayit's genomic testing services through a planned expanding network of 800 American Medical Center (AMC) facilities, staffed with medical doctors, nurses, pharmacists and other highly trained personnel. DHK Medical plans to provide walk-in medical services through its AMC facilities.

DHK will use Arrayit's patented and proprietary Variation Identification Platform™ (VIP) microarray technology and blood card collection procedure to offer genomic testing.

ARYC's VIP microarrays identify single nucleotide polymorphism (SNP) variants in a patient's DNA code in a rapid, affordable and highly accurate manner. DHK expects significant sales during the three-year contract. According to estimates given by DHK, ARYC could generate revenue of $16.8 million from the three-year contract.

Arrayit's technology is empowering DHK to capture the fast-growing Indian healthcare market by providing DNA testing services and unprecedented genomic information to medical professionals in real-time and on-location.

About Arrayit Corporation                           

Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company's innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit's products are used by nearly every major research center in the world.

About Liston Street Pulse                                                

Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second quarter ended June 30, 2013.


'/>"/>
SOURCE Arrayit Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MGC Diagnostics Corporation Reports 2013 Third Quarter Operating Results
2. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
3. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
4. Xi3 Corporation Signs Collaboration Agreement with Intermountain Healthcare as Founding Member of Intermountains New Healthcare Transformation Lab
5. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
6. Medbox Signs Multi-State Consulting Deal with X-Change Corporation
7. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
8. Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results
9. Omeros Corporation Reports Second Quarter 2013 Financial Results
10. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
11. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):